Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04292899 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,891
- Enrollment target
NCT04292899: Completed Phase 3 study, sponsored by Gilead Sciences.
NCT04292899 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 4,891 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (534% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04292899, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,891 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
Primary Outcome
Clinical status was derived from death, hospital discharge, and the ordinal scale as follows: score of "1" was used for all days on or after the date of death; score of "7" was used for all days on or after discharged alive date; last assessment carried forward for any missing values.The scale is as follows: 1. Death; 2. Hospitalized, on invasive mechanical ventilation or ECMO; 3. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring low flow supplemen
Interventions
- DRUG Standard of Care
- DRUG Remdesivir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,891 participants |
| Start Date | 2020-03-06 |
| Est. Completion | 2020-06-30 |
| Phase | Phase 3 |
What the finished NCT04292899 record still lists
NCT04292899 is an interventional study that assigns participants to a tested intervention. Its 4,891 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (534% higher).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT04292899 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04292899 about?
NCT04292899 is a clinical study titled "Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)". The primary objective of this study is to evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14.
What is the current status of trial NCT04292899?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,891 participants. The study started on 2020-03-06. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT04292899?
The interventions under investigation include: Standard of Care (DRUG), Remdesivir (DRUG).
Who is sponsoring clinical trial NCT04292899?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04292899's enrollment target sits among peer trials
4,891 52nd of 2000 higher than 1,949 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05929976 · 4,900 participants
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
- NCT01719055 · 4,800 participants
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain
- NCT05485675 · 4,800 participants · NA
Stand & Move at Work II: Effectiveness and Implementation of a Worksite Wellness Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI